|
|
||||||||||||||
|
|
|||||||||||||||
Therapeutics |
Clinical impact ratings Dermatology






Oncology 





Surgery 





Key Words: melanoma skin neoplams
| The first 150 words of the full text of this article appear below. |
METHODS
Design:
randomised controlled trial.
Allocation:
concealed.*
Blinding:
blinded (monitoring committee).*
Follow up period:
a median of 60 months.
Setting:
21 hospitals, 2 infirmaries, 1 cancer therapy network in the UK, and 1 cancer centre in Poland.
Patients:
900 patients >18 years of age (mean age 57 y, 52% men) who had a single primary localised cutaneous melanoma (
2 mm in thickness) on the trunk or limbs (excluding the palms of hands or the soles of the feet) where a 3 cm excision margin was technically possible. Exclusion criteria included pregnancy, a history of cancer (except basal cell carcinoma), and treatment with immunosuppressive agents.
Intervention:
primary tumour excision with a total surrounding margin of 1 cm (n = 453) or 3 cm (n = 447). All excisions were extended to or included the deep fascia.
Outcomes:
incidence of local, in transit, or nodal tumour recurrence and a composite endpoint comprising
Robin Marks, MBBS, MPH, MRACP, FACD, FRACP
St Vincents Hospital Melbourne
Melbourne, Victoria, Australia
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |